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The cardioprotection of the immature heart during cardiac surgery remains controversial
due to the differences between the adult heart and the newborn heart. Lysophosphatidic
acid (LPA) is a small bioactive molecule with diverse functions including cell proliferation
and survival via its receptor: LPA1–LPA6. We previously reported that the expressions
of LPA1 and LPA3 in rat hearts were much higher in immature hearts and then declined
rapidly with age. In this study, we aimed to investigate whether LPA signaling plays a
potential protective role in immature hearts which had experienced ischemia/reperfusion
(I/R) injury. The results showed that in Langendorff-perfused immature rat hearts
(2 weeks), compared to I/R group, LPA pretreatment significantly enhanced the cardiac
function, attenuated myocardial infarct size and CK-MB release, decreased myocardial
apoptosis and increased the expression of pro-survival signaling molecules. All these
effects could be abolished by Ki16425, an antagonist to LPA1 and LPA3. Similarly, LPA
pretreatment protected H9C2 from hypoxia-reoxygenation (H/R) induced apoptosis and
necrosis in vitro. The mechanisms underlying the anti-apoptosis effects were related
to activation of the phosphatidylinositol 3-kinase (PI3K)/protein kinas B (AKT) signaling
pathways as well as phosphorylation of the downstream effector of AKT, glycogen
synthase kinase 3 beta (GSK3β), through LPA1 and/or LPA3. What’s more, we found
that LPA preconditioning increased glucose uptake of H9C2 subjected to H/R by the
activation of AMP-Activated Protein Kinase (AMPK) but not the translocation of GLUT4.
In conclusion, our study indicates that LPA is a potent survival factor for immature hearts
against I/R injuries and has the potential therapeutic function as a cardioplegia additive
for infantile cardiac surgery.
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INTRODUCTION
Similar cardioprotection methods have been used in adult and pediatric groups for many years
(Turkoz, 2013). However, the immature heart is structurally, functionally, and metabolically
different to the adult heart. For example, the immature heart mainly prefers to utilize glucose as
its energy source rather than free fatty acids—which is the main substrate in the normal adult
heart (∼70%) (Onay-Besikci, 2006; Calmettes et al., 2015). Although the immature heart is more
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tolerant to ischemia, it is more vulnerable to reactive oxygen
species after reperfusion than the adult heart (Starnes et al., 1997).
Postoperative low cardiac output is still the major contributor to
morbidity and mortality in pediatric cardiac operations (Imura
et al., 2001). Nowadays the optimal myocardial protection
strategy for newborns undergoing congenital heart surgery
remains controversial. Therefore, it is necessary to explore an
optimal myocardial protection strategy for the immature heart.
Lysophosphatidic acid (LPA, 1-acyl-2-lyso-sn-glycero-
3-phosphate) is a simple endogenous bioactive phospholipid
possessing diverse functions, such as: neurogenesis, angiogenesis,
promoting cell migration and survival, as well as carcinogenesis
(Mutoh et al., 2012). Acting as an extra-cellular signaling
molecule, LPA exerts its function primarily through binding
to and activating six known G protein–coupled receptors
(GPCRS):LPA1–LPA6 (Hla et al., 2001; Choi et al., 2010). Our
previous study indicated that the expression of LPA receptor 1
and 3 peaked on postnatal 7d and 4d, respectively, and decreased
rapidly thereafter (Wang et al., 2012). Therefore, it reminds us of
its potential role in myocardial protection during the neonatal
period.
Apoptosis and necrosis are the primary pathologic factors
which lead to cardiomyocyte damage during I/R (Ma et al.,
2015; Wang et al., 2015). As a pro-survival factor, it is reported
that LPA could inhibit the apoptosis of diverse cells, such
as primary chronic lymphocytic leukemia cells, Schwann cells
and renal tubular cells (Levine et al., 1997; Weiner and Chun,
1999; Deng et al., 2003). The mechanism involved in this anti-
apoptosis procedure included activating the Hippo-pathway and
the PI3K/AKT pathway, as well as inhibiting the mitochondrial
intrinsic pathway; etc. (Hwang et al., 2014). Our earlier study also
demonstrated the anti-apoptosis function in mesenchymal stem
cells which had been subjected to ischemia (Chen et al., 2008).
Thus, we were interested in ascertaining whether LPA has an
anti-apoptosis role in immature heart I/R injury.
The enhanced glucose uptake and glycolysis have been shown
to be cardioprotective (Zhang et al., 2015) under pathological
conditions such as I/R. It is reported that LPA could stimulate
the glucose uptake of myotube, adipocyte (Yea et al., 2008),
FIGURE 1 | A schematic representation of the experimental protocol.
cumulus-oocyte complexes (Thomson et al., 1996) and ovarian
cancer cells (Kuwata et al., 2013). However, less is known about its
role and functional significance in immature myocardial glucose
uptake during I/R injury. Thus, we investigated whether LPA
could improve the glucose uptake in cardiomyocytes subjected
to IR injury.
Here, we hypothesized that LPA pretreatment may exert a
cardioprotective effect on the immature heart after ischemia
reperfusion injury by stimulating pro-survival signal pathways
as well as the uptake of glucose. We aimed to investigate a
potential cardioprotective agent for neonatal patients during
cardiac surgery.
MATERIALS AND METHODS
Animals
Males, 2 weeks Sprague–Dawley rats, 25–30 g body weight (BW),
were used for this study. Animals were fed a standard rat chaw
and allowed to drink water ad libitum. They were housed in
temperature-controlled (22–25◦C) cages with a 12-h dark and
12-h light cycle. This study protocol was approved by the Fuwai
Hospital Animal Care and Use Committee. The investigation
conforms with the “Guide for the Care and Use of Laboratory
Animals” published by the US National Institutes of Health (NIH
Publication No. 85-23, revised 1996) and the “Regulation to the
Care and Use of Experimental Animals” of the Beijing Council on
Animal Care (1996).
Langendorff Model and Study Design
After being heparinized (3 IU/g BW) and anesthetized with 50
mg/kg BW of sodium pentobarbital by intraperitoneal injection,
rats were subjected with amedian sternotomy and the hearts were
rapidly excised and placed in ice-cold heparinized K-H solutions.
The time taken from opening of the chest to excision of the heart
was 1–2 min. Immediately thereafter, the aorta was connected
to a standard Langendorff apparatus and perfused with Krebbs–
Henseleit (K-H) buffer solution (pH 7.4: in mM: NaCl 118; KCl
4.7; CaCl2 2.0; MgSO4 1.2; NaHCO3 25; KH2PO4 1.2; glucose
11.1), and continuously gassed with 95% O2 and 5% CO2 at
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pressure of 80 mmHg at 37◦C. A pulmonary arteriotomy
was performed to allow free drainage of coronary eﬄuent. A
water-filled latex balloon connected to a pressure transducer
was inserted into the left ventricle to assess the LV function.
Parameters, including heart rate (HR), left ventricle systolic
pressure (LVSP) and left ventricular end-diastolic pressure
(LVEDP), were continuously measured. The volume of the latex
balloon was adjusted to set LVEDP to 0–10 mmHg during the
stabilization phase.
Rats were randomly assigned to one of four experimental
groups. There were 6 rats in each group: (1) Sham group; (2)
I/R group; (3) I/R+LPA group; (4) I/R+Ki16425+LPA group.
The design of the experimental protocol is illustrated in Figure 1.
All hearts were equilibrated for 10 min followed by a 20-min
treatment period and subjected to 60 min of global ischemia by
stopping the K-H buffer perfusion (maintaining 37◦C), followed
by 30 min of reperfusion. LPA (10 µM) was added into the
perfusion fluid before ischemia and throughout reperfusion with
or without ki16425 (10 µM).
TABLE 1 | Baseline functional parameters in the Langendorff-perfused rat
groups.
SHAM
(n = 6)
IR
(n = 6)
LPA + IR
(n = 6)
KI + LPA + IR
(n = 6)
BW (g) 25.4 ± 0.4 26.1 ± 0.3 25.9 ± 0.5 27.4 ± 0.2
HW (mg) 130.7 ± 6.1 125.6 ± 5.4 127.9 ± 6.3 125.4 ± 4.2
LVSP (mmHg) 92 ± 5.7 93 ± 6.4 92 ± 5.3 90 ± 6.6
LVEDP (mmHg) 7.9 ± 0.7 7.8 ± 1.1 7.5 ± 0.6 7.7 ± 0.4
H R (beats/min) 315 ± 14 322 ± 16 319 ± 15 317 ± 13
CFR (ml/min) 2.1 ± 0.2 2.2 ± 0.5 2.0 ± 0.2 2.3 ± 0.4
All the values are expressed as mean± SEMs; BW, body weight; HW, heart weight; LVSP,
left ventricular systolic pressure; LVEDP, left ventricular diastolic pressure; HR, heart rate;
CFR, coronary flow rate.
FIGURE 2 | LPA pretreatment improved the cardiac function recovery of immature rats through LPA receptor 1/3 during myocardial I/R injury. (A–C)
Hemodynamic parameters (HR, LVSP, LVEDP) before ischemia (0 and 30 min) and 90, 105, 120 min during reperfusion in each group. LVSP indicates left ventricular
systolic pressure; LVEDP, left ventricular end diastolic pressure; HR, heart rate; IR, ischemia reperfusion. All values are expressed as mean ± SEM (n = 6 in each
group). **P < 0.01 vs. sham group; ##P < 0.01 vs. IR group; $P < 0.05 vs. IR + LPA group.
Assessment of Infarct Size
After 30min of reperfusion, the isolated hearts were removed and
cut into uniform sections of 2–3 mm thickness and incubated
for 20 min in 0.1 M sodium phosphate buffer containing 1%
2,3,5-triphenyl tetrazolium chloride (TTC) (Sigma–Aldrich, St.
Louis, MO, USA) at 37◦C. Viable myocardium showed up as
red, and the infarcted area showed up as pale white. The infarct
size was calculated using Image-Pro Plus software, and was
expressed as a percentage of the total heart size. The level
of creatine kinase-MB (CK-MB) was measured from coronary
eﬄuent which was collected while reperfusion took place, in
order to assess the infarct degree. The method of measurement
was by spectrophotometry, using commercial assay kits (Roche,
Indianapolis, IN, USA).
TUNEL Assay and Assessment of
Caspases Activity
The heart was fixed in neutral 10% formalin for 24 h,
embedded in paraffin, and cut into 8 µm-thick slices. After
de-paraffinating and re-hydratation, sections underwent antigen
retrieval by boiling in sodium citrate solution for 2 min.
TdT-mediated dUTP nick end labeling (TUNEL) staining
was performed using a fluorescence detection kit (Roche,
Indianapolis, IN, USA). Thereafter sections were covered
with Mounting Medium with DAPI (Invitrogen, California,
USA). Images were acquired using an Olympus fluorescence
microscope and counted using the Image- Pro Plus software
from 10 random fields at 400 × magnification. In order to
examine caspase-3 activity, commercial kit reagents (Biovision
Research Products, Mountain View, CA, USA), were used in
accordance with the procedures outlined by the manufacturer.
Samples of whole left ventricular homogenate were prepared
and tissues were homogenized in the cell lysis buffer followed
by centrifugation. The supernatant was collected and used for
the assay. Protein concentration in the lysate was measured
and 200 µg lysate protein was incubated in a 96-well plate
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with 2 × Reaction Buffer (50 µl) at 37◦C in the dark.
Caspase activity was monitored using a Microplate Reader at
405 nm.
Cell Culture
Embryonic rat heart derived H9C2 cells, from the cell bank at
the Shanghai Institute for Biological Sciences, were cultured in L-
DMEM (GIBCO, Grand Island, NY) supplemented with 10% FBS
(fetal bovine serum, GIBCO) and antibiotics (50 U/mL penicillin
and 50 µg/mL streptomycin, GIBCO) at 37◦C in a 95% room
air/5% CO2 incubator and sub-cultured when 80% confluence
was reached. Before different treatments to H9C2, the medium
would be replaced by serum-free DMEM when the H9C2 was
grown to 80% confluence. To establish an I/R model in vitro, a
Hypoxia-reoxygenation cell model was used in our study. Briefly,
after serum-starvation for 18 h and then treating with different
concentration of agents, H9C2 was subjected to hypoxia in a
controlled hypoxic plastic chamber for 12 h. Reoxygenation was
conducted in a normoxic incubator at 37◦C after hypoxia for 4 h.
For each evaluation, all experiments were conducted in triplicate.
Evaluation of Cell Viability and Apoptosis
Cell viability was measured using a quantitative colorimetric
assay with thiazolyl blue tetrazolium bromide (MTT, AMResco),
showing the mitochondrial activity of living cells. H9C2 cells
(∼3 × 104) were seeded in 24-well plates. After drug treatment
as indicated, cells were incubated with 300 µL MTT (final
concentration 0.5 mg/mL) for 4 h at 37◦C. The reaction was
terminated through the addition of 200 µL DMSO. The MTT
reaction products were determined by measuring the absorbance
at 630 nm in a CHAMELEONmicro-plate reader (HIDEX).
Hoechst 33258 (Invitrogen, California, USA) was used to
detect the apoptosis of H9C2 in different groups. Briefly, H9C2
was stained with Hoechst 33258 dye solution (5 µg/mL) for
20 min at room temperature, in darkness, and then examined
and photographed using a fluorescence microscope. Apoptotic
cells were identified as previously described. The percentage of
apoptotic cells was calculated as the ratio of the positive cell
number to the total cell number by Image J.
Flow Cytometry
The amounts of apoptotic cells induced by hypoxia-
reoxygenation were determined using an Annexin V-FITC
apoptosis detection kit (SIGMA, USA), according to the
manufacturer’s instructions, as previously described. Cells
in the initial stage of apoptosis were defined as annexin V
(+)/propidium iodide (PI) (−), while late apoptotic cells were
defined as annexin V (+)/PI (+). Briefly, H9C2 seeded in 6-wells
plates were washed twice with cold PBS, then harvested and
stained with 5 µl annexin V and 10 µl propidium iodide (PI)
per 500 µl cells for 15 min at RT in the dark. Flow cytometric
analyses were performed on a FACS Calibur Analyzer (BD). The
apoptotic cells, including annexin V+ /PI, were counted.
2-NBDG Uptake of H9C2
H9C2 was incubated with 2-NBDG, which is a fluorescent
glucose analog 2-(N-(7-nitrobenz-2-oxa-1, 3-diazol-4-yl)
amino)-2-deoxyglucose, to investigate the glucose uptake
ability. H9C2 was seeded in six-well plates. After hypoxia-
reoxygenation—as in a previous description—cell culture was
replaced by Kreb’s buffer without glucose (NaCl [145 mM],
KCl [5 mM], CaCl2 [6 mM], MgCl2 [1 mM], HEPES Na [25
mM], and NaHCO3 [10 mM], pH 7.4) and incubated with
different concentrations of LPA and insulin for 20 min at 37◦C.
Thereafter, 2-NBDG (100µM) (Invitrogen, California, USA) was
supplemented at the same culture temperature for an additional
FIGURE 3 | LPA pretreatment attenuates myocardium infract size and CK-MB release through LPA receptor 1/3 after I/R injury. (A) Representative
images of TTC staining in each group (n = 6, 4 slices per heart). The red-stained areas indicate viable tissue, and the non-stained pale areas indicate infarct tissue. (B)
Infarct size in each group. (C) Creatinine kinase, MB isoenzyme (CK-MB) activity in each group. All values are expressed as mean ± SEM (n = 6 in each group).
*P < 0.05 vs. sham group; **P < 0.01 vs. sham group, #p < 0.05 vs. IR group; $P < 0.05 vs. IR + LPA (10 µmol/L) group.
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10 min in the dark. Fluorescence was measured in a FACSCalibur
Analyzer (BD) by 488 nm (excitation wavelength) channel.
Data was collected from 20,000 events for each measured
sample.
Western Immunoblotting
After immunoblotting, the intensity of the immunoblot bands
was detected utilizing a ChemiDoc XRS+ (Bio-Rad) instrument.
Antibodies against the following proteins were purchased
from Cell Signaling Technology: anti-Bax (1:1,000), anti-
Bcl-2 (1:1,000), anti-GSK3beta (1:1,000), anti-phosphorylated
GSK3beta (1:1,000), anti-AKT (1:1,000), anti-p-AKT (Ser473;
1:1,000), anti-pThr172-AMPKα (1:1,000), anti-GLUT4 (1:500)
and anti-GAPDH (1:10,000; loading control) antibodies. In order
to measure the amount of GLUT4 in the plasma membrane, the
plasma membrane protein was separated from the cell by using a
compartmental protein extraction kit (Millipore, USA).
Statistical Analysis
SPSS16.0 for Windows (SPSS Inc, Chicago, III) was used for
data analysis. All values were expressed as mean ± standard
error of the mean (SEM). For comparisons between groups, the
one-way ANOVA or unpaired Student T-test, was used where
appropriate. Post hoc testing used a Bonferroni Correction for
multiple comparisons. If the test for normality failed or if the
sample was <5, a Fisher Exact Test was used. A P < 0.05 was
considered statistically significant.
RESULT
LPA Pretreatment Improved the Cardiac
Function Recovery of Immature Rats
through LPA Receptor 1/3 during I/R Injury
There were no significant differences among the groups
under basal conditions in cardiac LV function before the
start of ischemia (Table 1). After 60 min of global ischemia,
the I/R group exhibited a significant reduction in heart
rate (HR) (Figure 2A) and left ventricle systolic pressure
(LVSP) (Figure 2B) and a remarkable increase in LVEDP
(Figure 2C) (P < 0.01 vs. sham group, respectively). Compared
with the IR group, administration of LPA significantly
FIGURE 4 | LPA pretreatment attenuates the apoptosis of myocardium caused by ischemia and reperfusion through LPA receptor 1/3. (A)
Representative photographs of myocardial apoptosis by TUNEL assay in each group. The TUNEL positive cells are indicated by arrows. (B) Quantitative data on the
percentage of TUNEL-positive cells to total number of cells in each group. (C) Caspase-3 activity in each group. All values are expressed as mean ± SEM (n = 6 in
each group). **p < 0.01 vs. sham group, #P < 0.05 vs. IR group; $P < 0.05 vs. IR + LPA group.
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enhanced the recovery of HR, LVSP and LVEDP within
30 min of reperfusion (Figures 2A–C). Furthermore, the
administration of Ki16425 partially blocked the LPA-induced
improvement in ventricular systolic and diastolic function after
I/R (Figures 2A–C).
LPA Pretreatment Attenuates Myocardium
Infarct Size and Apoptosis through LPA
Receptor 1/3 after I/R Injury
The infarct size determined by TTC staining was significantly
lower in the IR+LPA group than in the IR group (Figures 3A,B).
However, the infarct-limiting effect of LPAwas abolished through
pretreatment with Ki16425 (Figures 3A,B). The released CK-
MB was also measured in each experimental group to determine
the degree of myocardial injury. Global ischemia followed
by reperfusion significantly increased CK-MB levels, and LPA
pretreatment significantly decreased the release of CK-MB
compared with IR group (Figure 3C). Similarly, these effects
were also partially abolished by Ki16425 (Figure 3C).
As displayed in Figures 4A,B, IR significantly increased the
percentage of TUNEL-positive cells. This increase was attenuated
through pretreatment with LPA, and Ki16425 attenuated the
anti-apoptotic effects of LPA. Consistent with the TUNEL data,
IR significantly increased the activity of infantile myocardial
caspase-3, which was rescued by pretreatment with LPA
(Figure 4C). Compared with the LPA group, co-administration
of LPA and Ki16425 significantly increased the apoptosis index
and the activity of caspase-3 (Figures 4B,C), which indicated
that LPA exerted its anti-apoptotic effects by coupling to its
receptor 1/3.
LPA Pretreatment Increased the
Expression of Pro-Survival Signaling
Molecules after IR Injury
Furthermore, the expression of classic anti-apoptotic (Bcl-
2) and pro-apoptotic proteins (Bax) were examined. IR
significantly reduced Bcl-2/Bax relative expression, and
pretreatment with LPA increased Bcl-2/Bax relative expression
(Figures 5A,B). In addition, western blot analyses of heart tissue
indicated that IR induced a statistically significant reduction
in the phosphorylation of AKT. LPA pretreatment markedly
elevated the phosphorylation of AKT and its downstream
molecule GSK-3β. However, those effects were abolished by
Ki16425 treatment (Figures 5C,D). These results indicate
that the cardioprotective effect of LPA is attributable to the
activation of the AKT signaling pathway through the LPA
receptor 1/3.
Pretreatment with LPA Attenuates
Hypoxia-Reoxygenation Induced
Apoptosis and Necrosis in Cultured H9C2
in vitro
Cell viability was decreased when H9C2 suffered from hypoxia-
reoxygenation (H/R) which was a cell model of ischemia
reperfusion (IR), as shown by the MTT assay. This change
was rescued by LPA pretreatment which was administered
in a dose-dependent manner (Figure 6C). Moreover, H/R
increased the number of apoptotic H9C2, as shown by
the Hoechst staining (Figure 6A). LPA preconditioning
significantly reduced the extent of H9C2 apoptosis compared
with the H/R group (Figure 6B). Apoptosis/necrosis was also
FIGURE 5 | LPA pretreatment increased the expression of pro-survival signaling molecules after IR injury. (A,B) Western blots analysis of the protein level
of Bcl-2 and Bax. (C,D) Western blots analysis of protein level of phosphorylated AKT, and phosphorylated GSK3b. All values are expressed as mean ± SEM (n = 3 in
each group). IR, ischemia reperfusion; Ki, ki16425. *P < 0.05 vs. sham group; #P < 0.05 vs. IR group; $P < 0.05 vs. IR + LPA group.
Frontiers in Physiology | www.frontiersin.org 6 March 2017 | Volume 8 | Article 153
Chen et al. Cardioprotection of LPA in Immature Heart
FIGURE 6 | LPA administration protects H9C2 from H/R induced cell apoptosis and death. (A,B) Representative images and quantitative data on H9C2
apoptosis obtained by Hochest staining (n = 3 in each experiment). (C) Cardiomyocytes viability after pretreatment with LPA (1, 10, or 25 µmol/L) with or without
suffering from H/R detected by MTT analysis. All values are expressed as mean ± SEM. *P < 0.05 vs. control; #P < 0.05 vs. H/R.
evaluated using the Annexin V-FITC Apoptosis Detection
Kit. The percentage of apoptosis and necrosis cells in the
IR group was significantly higher than the control group
(Figures 7A,B). LPA preconditioning significantly protected
H9C2 from H/R induced apoptosis. However, when LPA
administration was combined with PI3K/AKT inhibitor
LY294002, the anti-apoptosis effect of LPA was negated.
Consistently, the results of western blot indicated that IR
significantly reduced Bcl-2/Bax relative expression, and
pretreatment with LPA increased Bcl-2/Bax relative expression
(Figures 7C,D).
LPA Preconditioning Increased the
Glucose Uptake in H9C2 Cells Subjected to
Hypoxia-Reoxygenation
To investigate the effects of LPA preconditioning on
cardiomyocyte glucose uptake, the uptake of fluorescent
glucose (2-NBDG) was studied. As shown in Figures 8A,B,
after hypoxia 12 h, LPA (5 µM) significantly increased
2-NBDG uptake in H9C2. In the study, the Insulin (0.1
µM) treatment group was used as a positive control.
As expected, insulin increased glucose uptake faster
than LPA.
The Effect of LPA on GLUT4 Translocation
and AMPK Pathway
As shown in Figures 8C,D, there was no significant difference
between the control group and the LPA preconditioning group
on GLUT4 translocation from the cytoplasm to the membrane.
However, the insulin treatment group—which is a positive
control—showed a significant increase of GLUT4 translocation.
In addition, the role of AMP-Activated Protein Kinase (AMPK)
was investigated in this procedure. As shown in Figures 8C,E
preconditioning with 5 µM LPA significantly enhanced the
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FIGURE 7 | LPA pretreatment attenuates H/R induced apoptosis and necrosis in cultured H9C2 in vitro. (A) Representative images of H9C2
cardiomyocytes apoptosis detected by flow cytometry after staining with Annexin V and propidium iodide (PI) in each group. (B) Quantifications of the apoptotic
cardiomyocyte (Annexin V+/PI-)were presented as the percentage of total cells. (C,D) Western blots analysis of Bax and Bci-2. AII values are expressed as mean ±
SEM (n = 3 in each group). *P < 0.05 vs. ctrl group; **P < 0.01 vs. Ctrl group; #P < 0.05 vs. H/R group; $P < 0.05 vs. H/R + LPA group.
phosphorylation of AMPK (P < 0.05), while insulin did not.
These results suggested that LPA was involved in the activation
of AMPK pathway but not the translocation of GLUT4.
DISCUSSION
LPA, a bioactive molecule released by activated platelets under
pathological conditions, is involved in cardiovascular disease
(Abdel-Latif et al., 2015). Our previous study has documented
that LPA protects mesenchymal stem cells against ischemia-
induced apoptosis (Chen et al., 2008) and LPA1 and LPA3 are
highly expressed during the neonatal period (Wang et al., 2012).
However, little is known about the role of LPA on immature
hearts subjected to I/R injury. This study demonstrated for the
first time that LPA pretreatment significantly improved cardiac
function recovery in immature hearts following ischemia and
alleviated H/R injury in cultured H9C2. In addition, the effects
were dependent on the activation of LPA receptor 1 and/or 3.
The underlying protection mechanismmay be activating an anti-
apoptotic pathway and improving the uptake of glucose. These
results imply a protective effect of LPA in ischemia-reperfusion
(I/R) injury of immature hearts.
It is reported that current cardioplegic protection techniques
used in pediatric cardiac surgery do not take age into
consideration (Starnes et al., 1997; Imura et al., 2001).
Experimental studies have suggested that immature hearts are
resistant to ischemia, and recover from hypoxia more efficiently
than adult hearts (Liaw et al., 2013). However, compared to
adults, infants experienced significantly more reperfusion injury
and worse clinical outcomes (Starnes et al., 1997). In addition,
immature hearts responded less to most pharmacological
and physiological stimuli. Therefore, more specific cardiac
cardioplegia is necessary andmeaningful during pediatric cardiac
surgery. This study demonstrated (using a Langendoff model)
that LPA pretreatment could rescue the immature rat heart from
left ventricular dysfunction caused by 1 h ischemia and 30 min
reperfusion.
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FIGURE 8 | LPA pretreatment increased glucose uptake of H9C2 suffered from H/R. (A) Representative flow cytometry assay image of 2-NBDG uptake. (B)
The ratio of 2-NBDG uptake in each group. (C) H9C2 was stimulated with different concentration LPA to determine the phosphorylation level of AMPK at Thr 172 and
GLUT4 after H/R by performing Western blotting. (D) GLUT4 levels were normalized to GAPDH. (E) Phospho-AMPK levels were normalized to total AMPKa. All values
are expressed as mean ± SEM. *P < 0.05 vs. Ctrl; **P < 0.01 vs. Ctrl (H/R+0 µM LPA) group.
Wu et al. (2015) reported that cardiomyocyte apoptosis
directly resulted in heart dysfunction during IR injury (Peng
et al., 2011). Moreover, immature myocardium is more sensitive
to oxidative stress (Umansky et al., 1995). In our study, it
was found that I/R injury resulted in increasing apoptosis and
myocardial infarction size, which is consistent with the results
of other studies (Zhao, 2004; Ravingerová et al., 2013; Wang
et al., 2015). LPA has been reported to inhibit apoptosis of
various cells, such as cervical cancer cells, bone mesenchymal
stem cells, human dental pulp cells, etc. (Pan et al., 2014;
Sui et al., 2015). It was demonstrated here that LPA inhibits
apoptosis induced by ischemia reperfusion injury in immature
rat hearts and hypoxia-reoxygenation in H9C2. Furthermore,
the signaling pathways involved in LPA-induced anti-apoptotic
effects were investigated. PI3K/AKT activation has been reported
to be involved in left ventricular functional reserve, reduction
of apoptotic cardiomyocytes and limitation of infarct size (Fujio
et al., 2000). This study revealed that LPA significantly increased
the phosphorylation of AKT, as well as the ratio of Bcl-
2/Bax. Furthermore, in the I/R cell model, the AKT inhibitor
eliminated the anti-apoptotic effects of LPA. In the present study,
it was observed that LPA caused a significant increase in the
phosphorylation of GSK-3β at Ser9, which is an inactive form
of GSK-3β. Hence, this predicted that inhibition of downstream
GSK3β may have contributed to LPA-induced cardioprotection
by enhancing the Bcl-2/Bax ratios (Juhaszova et al., 2009). De
Sarno, et al, reported AKT activation improves cell survival
through phosphorylation of GSK-3β, and the inhibition of GSK-
3β reduces infarct size following focal cerebral ischemia in
vivo (De Sarno et al., 2002). Similarly, our data suggested that
PI3K/AKT-mediated deactivation of GSK-3β is, at the very least,
partially responsible for the anti-apoptotic effects of LPA.
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As subfamilies of G-protein-coupled receptors (GPCRs), LPA
receptors mediate a wide range of cellular functions, including:
inducing cell proliferation; regulating cell differentiation and
survival; and suppressing cell apoptosis, etc. (Goetzl and
An, 1998; Choi et al., 2010). Previous reports indicated
that LPA protects intestinal epithelial cells from apoptosis
through a mechanism involving LPA2/Erk/Bcl-2 signaling (Deng
et al., 2002). However, in our animal model study, Ki16425
administration before LPA preconditioning abolished cardiac
recovery in infantile hearts after I/R, and also eliminated the
anti-apoptotic effects by blockage of AKT phosphorylation.
The in vitro cell model also suggested that anti-apoptotic
effects were blunted by Ki16425. Our data suggested that LPA
protected immature hearts against IR injury through LPA1
and/or LPA3.
A shift in myocardial metabolism from fatty acid to glucose
occurs when hearts suffer from myocardial I/R, which is
more oxygen efficient and prevents deleterious effects (Lou
et al., 2013; Xue et al., 2015). Therefore, improvement of
glucose uptake will benefit the recovery of the infarcted
heart. This study indicated that LPA stimulated glucose uptake
when H9C2 was subjected to H/R. However, a significant
change of GLUT4 content in cytomembrane was not found.
In addition, we investigated the phosphorylation level of
AMPK at Thr172 which plays a key role in regulating cellular
energy metabolism. Indeed, we finally found that Phospho-
AMPK levels increased after LPA treatment. Consistently, the
phosphorylation of AMPK by LPA administration was also
founded in LPA-induced cell migration in ovarian cancer
cells (Kim et al., 2011) and the proliferation of diploid
fibroblasts (Kwon et al., 2010). Many papers have previously
stated that the activation of AMPK may result in stimulating
GLUT4 translocation and enhancing glycolysis (Lee et al.,
2015; Liang et al., 2015). Nevertheless, other studies indicated
that AMPK activation did not redistribute GLUT4 to the
sarcolemmal membrane (Lee et al., 2014). Taking this into
consideration, we concluded that LPA preconditioning could
increase the glucose uptake when H9C2 suffered from long-
term H/R through activating AMPK but independent of GLUT4
translocation.
Here we should confess that there are some limitations in
this study. The Langendorff heart perfusion system used in
this study is a classic model to evaluate the effect of drugs
on cardiac function ex vivo. However, Langendorff model
cannot mimic the in vivo environment which contains
mechanical and neurohumoral regulation. The in vivo
model by left anterior descending (LAD) ligation and re-
opening is the most representative of the clinical condition
of myocardial ischemia/reperfusion (I/R) injury (Chang
et al., 2012). As a result, further studies would be required
to clarify the influence of LPA on myocardial infarction
in vivo.
In conclusion, LPA preconditioning could prevent oxidative
stress induced cardiomyocyte apoptosis and increase glucose
uptake, finally improving the functional recovery of infantile
hearts after ischemia reperfusion. It also showed that the
effects were mediated through the LPA receptor 1 and/or
3/AKT/GSK3βpathways. These results clearly indicated
that LPA could potentially provide an effective therapeutic
benefit for infantile cardiac surgery as a cardioplegia
additive.
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